Boston Scientific Corporation $BSX Stock Position Boosted by Baird Financial Group Inc.

Key Points

• Baird Financial Group Inc. has increased its stake in Boston Scientific by 6.1% during Q1, now owning approximately $24.3 million in shares.
• Several hedge funds have also adjusted their positions, with institutional investors owning 89.07% of the company's stock.
• Despite recent insider sales, Boston Scientific's stock has been rated positively by analysts, with several raising their target prices to over $125.

Baird Financial Group Inc. increased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 6.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 241,117 shares of the medical equipment provider's stock after purchasing an additional 13,819 shares during the quarter. Baird Financial Group Inc.'s holdings in Boston Scientific were worth $24,324,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Colonial Trust Co SC grew its position in shares of Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after buying an additional 260 shares in the last quarter. Investment Management Corp VA ADV bought a new position in Boston Scientific during the 4th quarter valued at $25,000. Sunbeam Capital Management LLC bought a new position in Boston Scientific during the 4th quarter valued at $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific during the 1st quarter valued at $27,000. Finally, Ameriflex Group Inc. bought a new position in Boston Scientific during the 4th quarter valued at $31,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total value of $5,271,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $18,802,597.06. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have commented on BSX. Truist Financial increased their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Barclays increased their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Finally, Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $117.50.

Boston Scientific Stock Performance

BSX stock traded down $0.15 during mid-day trading on Friday, reaching $107.14. The company had a trading volume of 4,062,436 shares, compared to its average volume of 5,787,252. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $158.76 billion, a P/E ratio of 63.78, a P/E/G ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $108.94. The stock's 50-day simple moving average is $104.77 and its two-hundred day simple moving average is $102.20.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's quarterly revenue was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.